Kovina Therapeutics

What Kovina Therapeutics does

Kovina Therapeutics is a preclinical-stage biotechnology company incorporated in 2020 in Indianapolis, Indiana, that develops first-in-class small molecule antivirals targeting the HPV E6 oncoprotein to treat HPV-driven cancers — including cervical, oropharyngeal, anal, and genital cancers — as well as premalignant HPV infections such as cervical and anal dysplasia. The lead program consists of small molecules that selectively disable HPV E6 to restore p53 tumor suppressor activity, induce apoptosis and senescence in HPV-positive cancer cells, and suppress tumor growth in vivo, with the mechanism validated in a peer-reviewed PNAS publication in June 2026. The commercial opportunity sits inside an estimated 630,000 HPV-related cancer diagnoses annually, or roughly 5% of the global cancer burden; no directed antiviral therapy for HPV exists today, and the prophylactic HPV vaccine prevents new infections but does not treat existing ones.

The platform's intellectual property was licensed from Indiana University, where co-founders Dr. Elliot Androphy (Kampen-Norins Professor and Chair of Dermatology at IU School of Medicine, continuously NIH-funded for HPV research since 1987 and co-inventor of nusinersen, the first FDA-approved SMA treatment) and Dr. Samy Meroueh (Professor of biochemistry and molecular biology) initiated their HPV collaboration in 2017. The scientific advisory board features Karen Vousden (former Chief Scientist at Cancer Research UK and p53 authority), Homer Pearce (27-year Eli Lilly cancer drug discovery veteran behind GEMZAR and ALIMTA), Miguel Barbosa (former Global Head of Immunology Research at Janssen behind STELARA and TREMFYA), and Alberto Podjarny (structural chemist with published work on the HPV E6/E6AP/p53 complex).

Kovina generates no commercial revenue, has no approved products, and does not currently sell to end customers. Its forward business model contemplates licensing deals, pharmaceutical partnerships, or direct commercialization following IND filing and human clinical trials. To date, the company has been funded primarily through a $2 million seed round led by Elevate Ventures in October 2021 and approximately $2.975 million in non-dilutive NIH grants in 2022 (NCI Fast-Track STTR $2.4 million, NIAID SBIR Phase I $300,000, NIDCR SBIR Phase I $275,000). The company is privately held by Indiana-based life science investors and has not pursued public markets.

Name

Kovina Therapeutics

Legal name

Kovina Therapeutics, Inc.

Website

https://kovina.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Kovina Therapeutics is a preclinical-stage biotechnology company developing first-in-class small molecule antivirals targeting the HPV E6 oncoprotein to treat HPV-driven cancers and premalignant HPV infections in patients with existing disease.

Ownership category

akta.pro rank

Headquarters

HQ city

Indianapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Not yet generating revenue: Kovina Therapeutics is a preclinical-stage biotechnology company and is not yet generating revenue. The company is developing first-in-class antiviral therapeutics for HPV-related cancers and premalignant infections. Future revenue would likely come from pharmaceutical partnerships, licensing agreements, or direct commercialization of approved therapeutics.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Kovina Therapeutics is developing first-in-class small molecule antivirals that selectively target the HPV E6 oncogene to treat HPV-driven cancers and premalignant infections. The compounds inactivate HPV E6, restore p53 tumor suppressor function, and trigger apoptosis in HPV-infected cells while sparing healthy tissue, addressing the full spectrum of HPV disease from cervical, oropharyngeal, anal, and genital cancers to precancerous lesions such as cervical and anal dysplasia. The company is in preclinical development and has no commercial products available.

Product overview

Kovina Therapeutics is a preclinical stage biotechnology company developing a pipeline of first-in-class small molecule antiviral therapeutics targeting the HPV E6 oncoprotein. The company's core product is its HPV E6 Targeted Therapeutic program, which consists of small molecules designed to selectively kill HPV-infected cells by inactivating the HPV E6 oncogene. These compounds restore p53 tumor suppressor activity, induce apoptosis and senescence in HPV-positive cancer cells, and suppress tumor growth. The therapeutic approach addresses the full spectrum of HPV disease—from premalignant infections to invasive cancers—and represents a non-surgical treatment option for patients with HPV-related cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• HPV E6 Targeted Therapeutics Preclinical-stage first-in-class small molecule antivirals that selectively kill HPV-infected cells by inactivating the HPV E6 oncogene, restoring p53 tumor suppressor activity, inducing apoptosis and senescence in HPV-positive cancer cells, and suppressing tumor growth in vivo. Designed to treat the full spectrum of HPV disease from premalignant infections to invasive cancers including cervical, oropharyngeal, anal, and genital cancers. No commercial product is currently available.

Quantifiable outcome

• Restoration of p53 protein stability and activity in HPV-positive cancer cells
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core and minor.

• Indiana UniversitycoreStrategic or Co-development PartnerLicensed intellectual property from Indiana University. Founders include professors from IU School of Medicine. IU Innovation and Commercialization Office supported the company.
• Indiana Biosciences Research InstituteminorStrategic or Co-development PartnerListed as an investor and partner, validating the company's science and strategic vision.
• Cancer Drug Discovery and Development Alliance (CDDDA)minorStrategic or Co-development PartnerListed as a partner organization.
• Melanoma and Breast Cancer Centers of Concern (MBCCC)minorStrategic or Co-development PartnerListed as a partner organization.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kovina-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kovina Therapeutics